Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.

Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C.

Cardiovasc Res. 2019 Jun 7. pii: cvz153. doi: 10.1093/cvr/cvz153. [Epub ahead of print]

PMID:
31173066
2.

[Organoids: mini-organs at the service of biomedicine].

Galzi JL, Jouault T, Amédée J.

Med Sci (Paris). 2019 May;35(5):467-469. doi: 10.1051/medsci/2019091. Epub 2019 May 22. French. No abstract available.

PMID:
31115330
3.

[Gene editing in drug discovery and therapeutic innovation].

Galzi JL.

Med Sci (Paris). 2019 Apr;35(4):309-315. doi: 10.1051/medsci/2019068. Epub 2019 Apr 30. French.

PMID:
31038108
4.

Discovery of a Locally and Orally Active CXCL12 Neutraligand (LIT-927) with Anti-inflammatory Effect in a Murine Model of Allergic Airway Hypereosinophilia.

Regenass P, Abboud D, Daubeuf F, Lehalle C, Gizzi P, Riché S, Hachet-Haas M, Rohmer F, Gasparik V, Boeglin D, Haiech J, Knehans T, Rognan D, Heissler D, Marsol C, Villa P, Galzi JL, Hibert M, Frossard N, Bonnet D.

J Med Chem. 2018 Sep 13;61(17):7671-7686. doi: 10.1021/acs.jmedchem.8b00657. Epub 2018 Aug 28.

PMID:
30106292
5.

A strategy to discover decoy chemokine ligands with an anti-inflammatory activity.

Abboud D, Daubeuf F, Do QT, Utard V, Villa P, Haiech J, Bonnet D, Hibert M, Bernard P, Galzi JL, Frossard N.

Sci Rep. 2015 Oct 7;5:14746. doi: 10.1038/srep14746.

6.

New fluorescein precursors for live bacteria detection.

Guilini C, Baehr C, Schaeffer E, Gizzi P, Rufi F, Haiech J, Weiss E, Bonnet D, Galzi JL.

Anal Chem. 2015 Sep 1;87(17):8858-66. doi: 10.1021/acs.analchem.5b02100. Epub 2015 Aug 20.

PMID:
26260548
7.

[Quality control of chemical libraries].

Galzi JL, Ruggiu F, Gizzi P, Didier B.

Med Sci (Paris). 2015 Jun-Jul;31(6-7):660-6. doi: 10.1051/medsci/20153106020. Epub 2015 Jul 7. Review. French.

8.

Discovery and characterization of an endogenous CXCR4 antagonist.

Zirafi O, Kim KA, Ständker L, Mohr KB, Sauter D, Heigele A, Kluge SF, Wiercinska E, Chudziak D, Richter R, Moepps B, Gierschik P, Vas V, Geiger H, Lamla M, Weil T, Burster T, Zgraja A, Daubeuf F, Frossard N, Hachet-Haas M, Heunisch F, Reichetzeder C, Galzi JL, Pérez-Castells J, Canales-Mayordomo A, Jiménez-Barbero J, Giménez-Gallego G, Schneider M, Shorter J, Telenti A, Hocher B, Forssmann WG, Bonig H, Kirchhoff F, Münch J.

Cell Rep. 2015 May 5;11(5):737-47. doi: 10.1016/j.celrep.2015.03.061. Epub 2015 Apr 23.

9.

Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.

Lecat S, Belemnaba L, Galzi JL, Bucher B.

Cell Signal. 2015 Jul;27(7):1297-304. doi: 10.1016/j.cellsig.2015.03.016. Epub 2015 Mar 25.

PMID:
25817573
10.

A Fluorescent Live Imaging Screening Assay Based on Translocation Criteria Identifies Novel Cytoplasmic Proteins Implicated in G Protein-coupled Receptor Signaling Pathways.

Lecat S, Matthes HW, Pepperkok R, Simpson JC, Galzi JL.

Mol Cell Proteomics. 2015 May;14(5):1385-99. doi: 10.1074/mcp.M114.046698. Epub 2015 Mar 10.

11.

Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E, Guenot D.

Mol Cancer. 2014 Mar 14;13:58. doi: 10.1186/1476-4598-13-58.

12.

Quantitative structure-property relationship modeling: a valuable support in high-throughput screening quality control.

Ruggiu F, Gizzi P, Galzi JL, Hibert M, Haiech J, Baskin I, Horvath D, Marcou G, Varnek A.

Anal Chem. 2014 Mar 4;86(5):2510-20. doi: 10.1021/ac403544k. Epub 2014 Feb 12.

PMID:
24479843
13.

Plasma membrane translocation of REDD1 governed by GPCRs contributes to mTORC1 activation.

Michel G, Matthes HW, Hachet-Haas M, El Baghdadi K, de Mey J, Pepperkok R, Simpson JC, Galzi JL, Lecat S.

J Cell Sci. 2014 Feb 15;127(Pt 4):773-87. doi: 10.1242/jcs.136432. Epub 2013 Dec 11.

14.

Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands.

Daval SB, Kellenberger E, Bonnet D, Utard V, Galzi JL, Ilien B.

Mol Pharmacol. 2013 Jul;84(1):71-85. doi: 10.1124/mol.113.085670. Epub 2013 Apr 19.

PMID:
23604140
15.

An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.

Daubeuf F, Hachet-Haas M, Gizzi P, Gasparik V, Bonnet D, Utard V, Hibert M, Frossard N, Galzi JL.

J Biol Chem. 2013 Apr 26;288(17):11865-76. doi: 10.1074/jbc.M112.449348. Epub 2013 Feb 28.

16.

[G protein-coupled receptors: allosteric regulators of cell metabolism].

Galzi JL, Ilien B.

Med Sci (Paris). 2012 Oct;28(10):852-7. doi: 10.1051/medsci/20122810013. Epub 2012 Oct 12. Review. French.

17.

The chemokine CXCL12 is essential for the clearance of the filaria Litomosoides sigmodontis in resistant mice.

Bouchery T, Dénécé G, Attout T, Ehrhardt K, Lhermitte-Vallarino N, Hachet-Haas M, Galzi JL, Brotin E, Bachelerie F, Gavotte L, Moulia C, Bain O, Martin C.

PLoS One. 2012;7(4):e34971. doi: 10.1371/journal.pone.0034971. Epub 2012 Apr 12.

18.

Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.

Daval SB, Valant C, Bonnet D, Kellenberger E, Hibert M, Galzi JL, Ilien B.

J Med Chem. 2012 Mar 8;55(5):2125-43. doi: 10.1021/jm201348t. Epub 2012 Feb 27.

PMID:
22329602
19.

Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.

Gasparik V, Daubeuf F, Hachet-Haas M, Rohmer F, Gizzi P, Haiech J, Galzi JL, Hibert M, Bonnet D, Frossard N.

ACS Med Chem Lett. 2011 Dec 9;3(1):10-4. doi: 10.1021/ml200017d. eCollection 2012 Jan 12.

20.

TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Δ(9)-tetrahydrocannabiorcol.

Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Högestätt ED, Zygmunt PM.

Nat Commun. 2011 Nov 22;2:551. doi: 10.1038/ncomms1559.

PMID:
22109525
21.

A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome.

Chow KY, Brotin É, Ben Khalifa Y, Carthagena L, Teissier S, Danckaert A, Galzi JL, Arenzana-Seisdedos F, Thierry F, Bachelerie F.

Cell Host Microbe. 2010 Dec 16;8(6):523-33. doi: 10.1016/j.chom.2010.11.006.

22.

Contribution of a tyrosine-based motif to cellular trafficking of wild-type and truncated NPY Y(1) receptors.

Lecat S, Ouédraogo M, Cherrier T, Noulet F, Rondé P, Glasser N, Galzi JL, Mely Y, Takeda K, Bucher B.

Cell Signal. 2011 Jan;23(1):228-38. doi: 10.1016/j.cellsig.2010.09.007. Epub 2010 Sep 15.

23.

Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.

Galzi JL, Hachet-Haas M, Bonnet D, Daubeuf F, Lecat S, Hibert M, Haiech J, Frossard N.

Pharmacol Ther. 2010 Apr;126(1):39-55. doi: 10.1016/j.pharmthera.2009.12.003. Epub 2010 Feb 1. Review.

PMID:
20117133
24.

Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist.

Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, Bonnet D, Berdeaux A, Maigret B, Galzi JL, Hibert M, Llorens-Cortes C.

FASEB J. 2010 May;24(5):1506-17. doi: 10.1096/fj.09-140715. Epub 2009 Dec 29.

PMID:
20040517
25.

Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration.

Valant C, Maillet E, Bourguignon JJ, Bucher B, Utard V, Galzi JL, Hibert M.

J Med Chem. 2009 Oct 8;52(19):5999-6011. doi: 10.1021/jm900671k.

PMID:
19746979
26.

Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process.

Ilien B, Glasser N, Clamme JP, Didier P, Piemont E, Chinnappan R, Daval SB, Galzi JL, Mely Y.

J Biol Chem. 2009 Jul 17;284(29):19533-43. doi: 10.1074/jbc.M109.017145. Epub 2009 May 18.

27.

Small neutralizing molecules to inhibit actions of the chemokine CXCL12.

Hachet-Haas M, Balabanian K, Rohmer F, Pons F, Franchet C, Lecat S, Chow KY, Dagher R, Gizzi P, Didier B, Lagane B, Kellenberger E, Bonnet D, Baleux F, Haiech J, Parmentier M, Frossard N, Arenzana-Seisdedos F, Hibert M, Galzi JL.

J Biol Chem. 2008 Aug 22;283(34):23189-99. doi: 10.1074/jbc.M803947200. Epub 2008 Jun 13.

28.

Distinct motifs of neuropeptide Y receptors differentially regulate trafficking and desensitization.

Ouedraogo M, Lecat S, Rochdi MD, Hachet-Haas M, Matthes H, Gicquiaux H, Verrier S, Gaire M, Glasser N, Mély Y, Takeda K, Bouvier M, Galzi JL, Bucher B.

Traffic. 2008 Mar;9(3):305-24. Epub 2007 Dec 14.

29.

Topological analysis of the complex formed between neurokinin A and the NK2 tachykinin receptor.

Zoffmann S, Bertrand S, Do QT, Bertrand D, Rognan D, Hibert M, Galzi JL.

J Neurochem. 2007 Apr;101(2):506-16.

30.

A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties.

Maillet EL, Pellegrini N, Valant C, Bucher B, Hibert M, Bourguignon JJ, Galzi JL.

FASEB J. 2007 Jul;21(9):2124-34. Epub 2007 Mar 19.

PMID:
17371796
31.

Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.

Kellenberger E, Springael JY, Parmentier M, Hachet-Haas M, Galzi JL, Rognan D.

J Med Chem. 2007 Mar 22;50(6):1294-303. Epub 2007 Feb 21.

PMID:
17311371
32.

A rapid and versatile method to label receptor ligands using "click" chemistry: Validation with the muscarinic M1 antagonist pirenzepine.

Bonnet D, Ilien B, Galzi JL, Riché S, Antheaune C, Hibert M.

Bioconjug Chem. 2006 Nov-Dec;17(6):1618-23.

PMID:
17105244
33.

FRET and colocalization analyzer--a method to validate measurements of sensitized emission FRET acquired by confocal microscopy and available as an ImageJ Plug-in.

Hachet-Haas M, Converset N, Marchal O, Matthes H, Gioria S, Galzi JL, Lecat S.

Microsc Res Tech. 2006 Dec;69(12):941-56.

PMID:
17080432
34.

On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies.

Tahtaoui C, Guillier F, Klotz P, Galzi JL, Hibert M, Ilien B.

J Med Chem. 2005 Dec 1;48(24):7847-59.

PMID:
16302823
35.

Detection of human immunodeficiency virus type 1 Nef and CD4 physical interaction in living human cells by using bioluminescence resonance energy transfer.

Cluet D, Bertsch C, Beyer C, Gloeckler L, Erhardt M, Gut JP, Galzi JL, Aubertin AM.

J Virol. 2005 Jul;79(13):8629-36.

36.

Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties?

Baurand A, Eckly A, Hechler B, Kauffenstein G, Galzi JL, Cazenave JP, Léon C, Gachet C.

Mol Pharmacol. 2005 Mar;67(3):721-33. Epub 2004 Dec 15.

PMID:
15602005
37.

Dynamic confinement of NK2 receptors in the plasma membrane. Improved FRAP analysis and biological relevance.

Cézanne L, Lecat S, Lagane B, Millot C, Vollmer JY, Matthes H, Galzi JL, Lopez A.

J Biol Chem. 2004 Oct 22;279(43):45057-67. Epub 2004 Aug 3.

38.

Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor.

Tahtaoui C, Parrot I, Klotz P, Guillier F, Galzi JL, Hibert M, Ilien B.

J Med Chem. 2004 Aug 12;47(17):4300-15.

PMID:
15294002
39.

Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties.

Ilien B, Franchet C, Bernard P, Morisset S, Weill CO, Bourguignon JJ, Hibert M, Galzi JL.

J Neurochem. 2003 May;85(3):768-78.

40.
41.
42.

Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor.

Gicquiaux H, Lecat S, Gaire M, Dieterlen A, Mély Y, Takeda K, Bucher B, Galzi JL.

J Biol Chem. 2002 Feb 22;277(8):6645-55. Epub 2001 Dec 7.

43.

The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states.

Palanche T, Ilien B, Zoffmann S, Reck MP, Bucher B, Edelstein SJ, Galzi JL.

J Biol Chem. 2001 Sep 14;276(37):34853-61. Epub 2001 Jul 17.

44.

Neurotoxicity of channel mutations in heterologously expressed alpha7-nicotinic acetylcholine receptors.

Lukas RJ, Lucero L, Buisson B, Galzi JL, Puchacz E, Fryer JD, Changeux JP, Bertrand D.

Eur J Neurosci. 2001 May;13(10):1849-60.

PMID:
11403678
45.

Optimal inhibition of X4 HIV isolates by the CXC chemokine stromal cell-derived factor 1 alpha requires interaction with cell surface heparan sulfate proteoglycans.

Valenzuela-Fernández A, Palanche T, Amara A, Magerus A, Altmeyer R, Delaunay T, Virelizier JL, Baleux F, Galzi JL, Arenzana-Seisdedos F.

J Biol Chem. 2001 Jul 13;276(28):26550-8. Epub 2001 May 14.

46.
47.

Subcellular compartmentalization of activation and desensitization of responses mediated by NK2 neurokinin receptors.

Vollmer JY, Alix P, Chollet A, Takeda K, Galzi JL.

J Biol Chem. 1999 Dec 31;274(53):37915-22.

48.

Molecular basis of the charge selectivity of nicotinic acetylcholine receptor and related ligand-gated ion channels.

Corringer PJ, Bertrand S, Galzi JL, Devillers-Thiéry A, Changeux JP, Bertrand D.

Novartis Found Symp. 1999;225:215-24; discussion 224-30. Review.

PMID:
10472058
49.
50.

Mutational analysis of the charge selectivity filter of the alpha7 nicotinic acetylcholine receptor.

Corringer PJ, Bertrand S, Galzi JL, Devillers-Thiéry A, Changeux JP, Bertrand D.

Neuron. 1999 Apr;22(4):831-43.

Supplemental Content

Support Center